Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android


Cryoglobulinemia at a Glance
  • Cryoglobulins are circulating immunoglobulin complexes found in plasma or serum that reversibly precipitate in cold temperatures.
  • Cryoglobulinemia may be symptomless or cause a clinical syndrome involving the skin: purpura at distal sites is the hallmark. Livedo reticularis, acrocyanosis, ulceration, or gangrene may also be seen.
  • Cryoglobulins are classified based on molecular properties into types I, II, III (Brouet classification).
  • Type I cryoglobulins consist of a single monoclonal immunoglobulin (typically IgG) or light chain. They occur with hematologic malignancies such as multiple myeloma. If symptomatic, they present with a noninflammatory occlusive vasculopathy.
  • Type II cryoglobulins consist of a monoclonal immunoglobulin (typically IgM) complexed with a polyclonal immunoglobulin (typically IgG).
  • Type III cryoglobulins consist of purely polyclonal immunoglobulin complexes; type II–III refers to an intermediate state with oligoclonal immunoglobulin.
  • Types II and III are also referred to as mixed cryoglobulinemias. They are caused by chronic hepatitis C virus (HCV) infection in >90% of cases, while in a minority of cases no etiology can be identified, designating them as “essential mixed” cryoglobulinemias. They present as the cryoglobulinemic vasculitis syndrome, i.e., an immune complex vasculitis involving the skin, neural, and renal tissues.
  • Therapy primarily consists of controlling the underlying malignancy or HCV infection. In addition, immunosuppressants, plasma exchange, or targeting of cryoglobulin-producing B-cell clones may alleviate the cryoglobulin burden.

Cryoglobulinemia may be a symptomless phenomenon that is incidentally found, or it may produce a clinical syndrome involving the skin as a primary organ. In a historic large-scale examination, 11% of patient sera were shown to have cyoglobulinemia, but detection rates vary greatly with the patient population studied.1 Reliable figures on the incidence or prevalence of cryoglobulinemia or symptomatic cryoglobulinemic syndrome are lacking. The epidemiologic study is hampered by factors such as selection bias from the referral of patients to tertiary care hospitals, by the heterogeneity of clinical presentations inclusion criteria, and by the different geographic distribution of underlying etiologies such as HCV infection. There is a geographic predominance of cryoglobulinemia in Southern Europe as compared to Northern Europe or the United States that might be explained by this latter fact. The frequency distribution of different cryoglobulinemia subtypes among all types of cryoglobulinemia is approximately type I 25%, type II 25%, type III 50%, making the mixed cryoglobulinemias (types II and III) the most abundant form.2 The vast majority (>90%) of mixed cryoglobulinemias occurs in association with chronic HCV infection. Thus, HCV-associated mixed cryoglobulinemia is the form among all cryoglobulinemias that has been studied best. On average, 30% of chronically HCV-infected subjects develop cryoglobulinemia, and this proportion can go up to 90% when patients with very longstanding disease are examined.35 Development of cryoglobulins is more frequent with HCV genotype 1 as compared to genotypes 2 and 3.6 However, on average, the symptomatic cryoglobulinemic vasculitis syndrome is present in only 2% to 5% of chronically HCV-infected patients7 though figures as high as ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.